# Appropriateness of Ketoanalogues of Amino Acids, Calcium Citrate, and Inulin Supplementation for CKD Management: A RAND/UCLA Consensus

**Authors:** Nadia Saavedra-Fuentes, Enrique Carmona-Montesinos, Gilberto Castañeda-Hernández, Israel Campos, Juan Carlos Castillo-Salinas, Javier Alberto Castillo-Tapia, Karla Guadalupe Del Castillo-Loreto, Juan Carlos Falcón-Martínez, Raquel Fuentes-García, Miguel Ángel García de León Guerrero, Victor García-García, Erika F. Gómez-García, Rafael González-Toledo, Angélica Jaime, Kely Rely, Claudia Lerma, Luis E. Morales-Buenrostro, Mateo Quilantan-Rodriguez, Adrián Rodriguez-Matías, Felipe Octavio Rojas-Rodriguez, Rafael Valdez-Ortiz, Michael Wasung, Berenice Ceron-Trujillo, Edgar Ramirez-Ramirez

PMC · DOI: 10.3390/nu16172930 · 2024-09-02

## TL;DR

Experts evaluated supplements for chronic kidney disease and concluded that certain amino acid analogs, calcium citrate, and inulin are appropriate for managing the condition.

## Contribution

Generated consensus-based guidance on the appropriateness of specific supplements for CKD management.

## Key findings

- Ketoanalogues of amino acids are appropriate for low-protein diets to reduce CKD manifestations.
- Calcium citrate is appropriate to reduce CKD symptoms.
- Inulin is appropriate to delay CKD outcomes and manage comorbidities.

## Abstract

Background: Current treatment for chronic kidney disease (CKD) focuses on improving manifestations and delaying progression. Nutritional approaches play a crucial role in CKD management, and various supplements have become available. Ketoanalogues of amino acids (KAs), calcium citrate, and inulin have been proposed as suitable supplements, yet their widespread use has been limited due to insufficient evidence. This study aimed to generate general guidance statements on the appropriateness of these supplements through a RAND/UCLA consensus process. Methods: A RAND/UCLA consensus panel was convened to evaluate the appropriateness of these supplements in different clinical scenarios. In this study, we present a subgroup analysis focusing on a panel of eleven clinical nephrologists from among the experts. Results: Supplementation of low-protein diets (LPDs) and very low-protein diets (VLPDs) with KA was considered appropriate to reduce manifestations and delay CKD outcomes, supplementation with calcium citrate is considered appropriate to reduce CKD manifestations, and supplementation with inulin is considered appropriate to delay CKD outcomes and manage comorbidities. Conclusions: Based on a combination of clinical experience and scientific evidence, the panel reached a consensus that KA supplementation of LPD and VLPD, calcium citrate, and inulin are appropriate in patients with CKD across various scenarios.

## Linked entities

- **Chemicals:** calcium citrate (PubChem CID 13136)
- **Diseases:** chronic kidney disease (MONDO:0005300)

## Full-text entities

- **Diseases:** CKD (MESH:D051436)
- **Chemicals:** Amino Acids (MESH:D000596), KA (-), Calcium Citrate (MESH:D019355), Inulin (MESH:D007444)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11397001/full.md

---
Source: https://tomesphere.com/paper/PMC11397001